brainsway vs neurostar: Cost and Practice Fit

The Quick Verdict

NeuroStar is usually the cleaner fit for a practice that wants a lower capital commitment, a focused figure-eight coil, and a familiar standard TMS workflow. The price gap is meaningful before a clinic has treated its first patient.

BrainsWay Deep TMS fits a practice that specifically wants the H-Coil approach and is comfortable paying more for the system. That may make sense for a clinic whose physicians, referral partners, and patient population already favor Deep TMS.

Neither purchase should be treated as objective superiority. The equipment needs to fit the program you can operate well. A system that looks attractive in a manufacturer presentation can become a literal money pit if the clinic has weak referrals, poor authorization processes, or no plan for technician coverage.

The purchase decision also has a used-market angle. A lower-cost used system can change the economics for an independent practice, particularly when the alternative is delaying the launch entirely. Review the used Brainsway Deep TMS market alongside dealer quotes before treating the new-equipment list price as the only available path.

Device Costs Side by Side

A new NeuroStar system runs $80,000-$150,000, with used units at $40,000-$80,000. A new BrainsWay Deep TMS system runs $100,000-$200,000, with used units at $50,000-$120,000. Source

The spread within each range matters. Equipment age, included accessories, service status, seller support, installation requirements, and the commercial structure of the deal can all affect what a clinic pays. The published range gives you a starting point for diligence, not a substitute for a written quote.

A lower purchase price can give NeuroStar an advantage for a new program that needs to preserve capital for marketing, hiring, leasehold changes, and working capital. TMS clinics often focus on the machine because it is the visible line item. The harder part is funding the operation while referrals and reimbursements build.

BrainsWay asks for more capital at the outset. That does not make it a poor purchase. It means the clinic should have a clear reason for choosing the H-Coil platform and a concrete plan for patient flow. If the technology matches the practice’s clinical philosophy and referral network, the higher acquisition cost may be acceptable.

What NeuroStar Costs

A new NeuroStar system runs $80,000-$150,000, with used units at $40,000-$80,000. Source

That spread creates a practical choice. New equipment may appeal to a clinic that wants manufacturer support and a current system from the beginning. Used equipment can reduce the entry cost for a practice that has the operational expertise to inspect the system, verify service history, and understand what is included in the sale.

NeuroStar’s standard protocol is 36 sessions over 9 weeks. Source That treatment structure affects technician scheduling, chair capacity, authorization work, and how a clinic forecasts revenue from a patient course.

Both devices bill $300-$500 per session and are insurance reimbursable. Source The published per-session range is useful, but a clinic should model reimbursement using its own payer mix. Contracted rates, denials, documentation requirements, and authorization delays can make the economics look sharply different from a broad billing range.

NeuroStar consumables run $2,000-$5,000 annually in treatment caps, and both devices carry $5,000-$10,000 annual maintenance. Source The caps are the recurring cost that buyers should put directly into the operating model. They are easy to overlook when the purchase conversation is centered on the machine price.

Maintenance deserves the same attention. A clinic that has patients scheduled cannot casually absorb downtime. Ask what the service arrangement covers, who handles issues locally, what replacement process applies, and what support looks like after the initial commercial period. Those answers shape the operational risk far more than a polished brochure does.

NeuroStar’s focused figure-eight coil approach may be familiar to clinicians who trained or worked with conventional TMS systems. That familiarity can reduce friction during implementation. It does not remove the need for staff training, patient education, careful mapping, or reliable clinical oversight.

What BrainsWay Deep TMS Costs

A new BrainsWay Deep TMS system runs $100,000-$200,000, with used units at $50,000-$120,000. Source

The used range is especially important for buyers evaluating whether Deep TMS is financially realistic for their practice. A used system may narrow the entry-price gap, although it also increases the need for careful inspection. Clinics should verify service history, compatibility, included components, installation responsibilities, and the availability of support before they commit.

BrainsWay runs 20-30 sessions. Source A shorter reported session count than NeuroStar’s standard protocol can affect patient scheduling and course planning. It should not be treated as a universal financial advantage. The clinic still needs to understand the applicable cleared indication, clinical protocol, reimbursement rules, and physician judgment behind treatment planning.

Both devices bill $300-$500 per session and are insurance reimbursable. Source BrainsWay buyers should run those session economics through the actual payer contracts and patient mix they expect to serve. Reimbursement is a business process, not a feature of the device.

Both devices carry $5,000-$10,000 annual maintenance. Source The maintenance line is similar across the platforms, which puts more focus on the initial purchase gap and NeuroStar’s recurring caps. A clinic choosing BrainsWay should be able to explain why the H-Coil platform earns its place in the budget.

The H-Coil is the central technology distinction. BrainsWay positions Deep TMS around deeper brain stimulation, while NeuroStar uses focused figure-eight coil stimulation. That difference affects how the device is discussed with clinicians and patients, how staff learn the workflow, and what a practice emphasizes in its local market.

For a closer look at the company behind the platform, see the Brainsway manufacturer profile. Manufacturer information can help with due diligence, but the final equipment decision should still come from your own clinical and financial model.

Total Cost of Ownership: Where They Diverge

NeuroStar consumables run $2,000-$5,000 annually in treatment caps; both devices carry $5,000-$10,000 annual maintenance. Source

That is the cleanest total-cost distinction between the systems. NeuroStar starts at a lower reported purchase range, then adds a recurring treatment-cap expense. BrainsWay begins with a higher reported system price and uses its helmet-style H-Coil design rather than treatment caps.

A buyer should avoid treating either line item in isolation. Lower acquisition cost can be offset by recurring consumables over the life of the program. Higher acquisition cost can place more pressure on the clinic’s launch plan and cash reserves. The right model puts equipment, maintenance, consumables, staffing, training, space, referrals, payer timing, and downtime into the same spreadsheet.

The decision also changes with scale. A clinic with a modest expected patient flow may care most about reducing the cash required to get started. A clinic with an established referral base may care more about the platform it believes will support its clinical offering and local market position. Those are different businesses wearing the same specialty label.

The useful question is not which device wins a generic comparison. Ask which cost structure your practice can carry while still delivering a consistent patient experience. If that answer is vague, the equipment purchase is premature.

Technology, FDA Clearance, and Evidence

NeuroStar uses Transcranial Magnetic Stimulation with a focused figure-eight coil. BrainsWay Deep TMS uses H-Coil technology for deeper brain stimulation. Both sit in the same TMS device category, but they give a practice different clinical and operational stories to tell.

NeuroStar was FDA cleared in 2008 and BrainsWay Deep TMS in 2013. Source Clearance dates do not decide the purchase, but they establish that both systems have been in the US market for a substantial period.

NeuroStar’s evidence base spans 100+ published studies. Source A clinic should still review evidence through the lens of the indication it plans to treat, its physician leadership, and the claims it is prepared to make publicly.

Both systems have FDA-cleared indications, and those indications should guide how the practice presents treatment to patients and referral sources. Sales representatives may make broad comparisons because their job is to sell a platform. Your job is to choose equipment that supports clinically responsible care and a durable practice.

This is also where the independent-comparison frame matters. The figure-eight coil and H-Coil are different approaches. They are not interchangeable talking points. A clinic should understand the mechanism, the patient experience, the workflow, and the evidence before adopting either one.

Which Practice Fits Each Device?

NeuroStar may fit a practice that wants the lower reported capital range and is comfortable budgeting for treatment caps. It can also fit clinics that prefer a focused figure-eight coil workflow and want a conventional TMS setup that staff and referring clinicians readily understand.

BrainsWay Deep TMS may fit a practice that wants H-Coil technology and has a clear commercial and clinical reason to pay more for the platform. The system may be easier to justify when physician preference, referral relationships, or the clinic’s care model already support that choice.

The best buyer prepares a simple decision file before speaking with vendors. Include the purchase quote, used-equipment alternatives, maintenance terms, consumables, installation needs, training requirements, staffing coverage, payer assumptions, and projected patient flow. Then have clinical leadership review the platform against the cleared indications the practice intends to offer.

If your clinic also evaluates adjacent equipment categories, the pain management category can help place TMS within a broader equipment strategy. A specialty practice can make sensible equipment choices one at a time and still create a messy overall capital plan.

Manufacturers will frame the choice around their strengths. That is expected. A clinic owner should frame it around the business and care model that will exist after the sales process ends.

The decision is about practice fit, not objective superiority. Can your clinic support the cost structure, workflow, and clinical story of the platform it chooses?